2273 related articles for article (PubMed ID: 8196915)
1. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK.
Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y
Oncology; 1994; 51(3):296-302. PubMed ID: 8196915
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
3. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
4. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
6. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
Lala PK; Elkashab M; Kerbel RS; Parhar RS
Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
[TBL] [Abstract][Full Text] [Related]
7. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y
Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
[TBL] [Abstract][Full Text] [Related]
8. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
Nomi S; Naito K; Kahan BD; Pellis NR
Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.
Parhar RS; Lala PK
J Exp Med; 1987 Jan; 165(1):14-28. PubMed ID: 3491867
[TBL] [Abstract][Full Text] [Related]
10. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
11. The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.
Palomares T; Bilbao P; Alonso-Varona A; Barberá-Guillem E
Cancer Immunol Immunother; 1995 May; 40(5):292-8. PubMed ID: 7600560
[TBL] [Abstract][Full Text] [Related]
12. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
13. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
Rinehart JJ; Triozzi PL; Lee MH; Aldrich W; Young D
Mol Biother; 1992 Jun; 4(2):77-82. PubMed ID: 1515098
[TBL] [Abstract][Full Text] [Related]
14. [Regional adoptive immunotherapy using activated lymphocytes].
Ebina T; Isono N; Murata K; Yokoyama J; Mikuni J; Ohuchi K
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1549-52. PubMed ID: 8854802
[TBL] [Abstract][Full Text] [Related]
15. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
16. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
18. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
20. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma.
Guan H; Nagarkatti PS; Nagarkatti M
J Immunol; 2007 Sep; 179(6):3715-23. PubMed ID: 17785808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
